pone.0245235.g002.tif (514.22 kB)

Fig 2 -

figure

posted on 2021-01-27, 18:23 authored by Shinichi Ishiguro, Tetsuro Shinada, Zhou Wu, Mayumi Karimazawa, Michimasa Uchidate, Eiji Nishimura, Yoko Yasuno, Makiko Ebata, Piyamas Sillapakong, Hiromi Ishiguro, Nobuyoshi Ebata, Junjun Ni, Muzhou Jiang, Masanobu Goryo, Keishi Otsu, Hidemitsu Harada, Koichi Suzuki

Relationship among Naturido and cell proliferation (A), therapeutic agents (B), acetylcholinesterase inhibitory activity (C), and the gene expression (D). (A) Normal human dermal fibroblasts (NHDFs), human hepatocellular carcinoma (HepG2) cells, human myeloid leukaemia (K562) cells and C6 glial tumour cells were used for proliferation assays with WST-1 (%) after treatment with Naturido at concentrations of 2.5 and 25 μM. (B) Each therapeutic agent (zonisamide, donepezil, eserine, and galantamine) was used at the same concentration as Naturido (25 μM), and proliferation was measured with a BrdU assay (%). (C) Comparison of the inhibitory effects of Naturido and donepezil on acetylcholinesterase (AChE) activity, shown as AChE inhibition (%). (D) The mRNA expression levels of representative neurotrophic factors (nerve growth factor = NGF, brain-derived neurotrophic factor = BDNF, vascular endothelial growth factor = VEGF-A, glial cell line-derived neurotrophic factor = GDNF, and non-acronymic neuropeptide = VGF) in astrocyte cultures were investigated to determine whether Naturido treatment enhances the expression of these genes. The Naturido concentration was 25 μM. All values are expressed as means ± SEMs. *P < 0.05, **P< 0.01, ***P < 0.001, **** P < 0.0001 vs each group (A-C Tukey-Kramer test using JMP 10.0.0) and vs the value at 24 h (D, t-test using JMP 10.0.0).